Results 21 to 30 of about 45,621 (284)

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
A. Nguyen, L. Cavallari, J. Rossi, G. Stouffer, Craig R. Lee   +4 more
semanticscholar   +1 more source

Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study

The Pharmacogenomics Journal, 2022
Variation within the CYP2C19 gene has been linked to differential metabolism of selective serotonin reuptake inhibitors (SSRIs). Pharmacogenetic recommendations based on the effect of CYP2C19 variants have been made available and are used increasingly by
A. Campos, Enda M. Byrne, B. Mitchell, N. Wray, P. Lind, J. Licinio, S. Medland, N. G. Martin, I. Hickie, M. Rentería   +9 more
semanticscholar   +1 more source

Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study. [PDF]

, 2020
Determining factors that contribute to interindividual and intra-individual variability in pharmacokinetics (PKs) and drug metabolism is essential for the optimal use of drugs in humans.
Alhaja, Maher, Dorrestein, Pieter C, Jarmusch, Alan K, Knight, Rob, Liyanage, Marlon, Ma, Joseph D, Momper, Jeremiah D, Tsunoda, Shirley M, Vrbanac, Alison   +8 more
core   +1 more source

CYP2C19 Genetic Polymorphism in the East of Iran: Its Association with the Severity and Pattern of Coronary Artery Disease [PDF]

Journal of Cardio-Thoracic Medicine, 2019
Introduction: Since there has been a dearth of research on the assessment of CYP2C19 polymorphism in the east of Iran (Khorasan provinces), this study aimed to detect, CYP2C19*2 and CYP2C19*3 allele frequencies among patients with coronary artery disease.
Mahdi Zahedi, Mahmoud Shabestari, Hossein Ayatollahi, Arash Gholoobi   +3 more
doaj   +1 more source

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. [PDF]

JACC: Cardiovascular Interventions, 2018
OBJECTIVES: This multicenter pragmatic investigation assessed outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention (PCI).
L. Cavallari, Craig R. Lee, A. Beitelshees, R. Cooper-DeHoff, Julio D. Duarte, D. Voora, Stephen E. Kimmel, C. McDonough, Y. Gong, Chintan V. Dave, Victoria M. Pratt, T. Alestock, R. D. Anderson, Jorge A. Alsip, A. Ardati, B. Brott, Lawrence Brown, Supatat Chumnumwat, Michael J. Clare-Salzler, James C. Coons, Joshua C. Denny, C. Dillon, Amanda R. Elsey, Issam S. Hamadeh, S. Harada, W. Hillegass, L. Hines, R. Horenstein, L. A. Howell, Linda J. B. Jeng, M. Kelemen, Yee Ming Lee, O. Magvanjav, M. Montasser, David R. Nelson, E. Nutescu, Devon Nwaba, R. Pakyz, Kathleen Palmer, Joshua F. Peterson, T. Pollin, Alison H. Quinn, S. Robinson, Jamie A. Schub, Todd C. Skaar, D. M. Smith, Vindhya B. Sriramoju, P. Starostik, Tomasz P. Stys, J. M. Stevenson, Nicholas Varunok, M. Vesely, Dyson T Wake, K. Weck, K. Weitzel, R. Wilke, J. Willig, Richard Y Zhao, R. Kreutz, G. Stouffer, P. Empey, N. Limdi, A. Shuldiner, A. Winterstein, Julie A. Johnson   +64 more
semanticscholar   +3 more sources

Toward a More accurate, Evidence-Based Classification of CYP Inhibitors: A Critical Appraisal of Current Systems. [PDF]

Clin Pharmacol Ther
In this issue of CPT, Malavé et al. deliver a comprehensive reassessment of CYP2C19 inhibitor classifications through a systematic review of clinical drug–drug interaction (DDI) studies. While their findings bring clarity to specific discrepancies, this commentary explores the origins of such inconsistencies, particularly focusing on methodological ...
Backman JT.
europepmc   +2 more sources

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

Translational Psychiatry, 2022
Cytochrome P450 drug-metabolizing enzymes may contribute to interindividual differences in antidepressant outcomes. We investigated the effects of CYP2C19 and CYP2D6 gene variants on response, tolerability, and serum concentrations.
Farhana Islam, Victoria S. Marshe, Leen Magarbeh, B. Frey, R. Milev, Claudio N. Soares, S. Parikh, F. Placenza, S. Strother, S. Hassel, V. Taylor, F. Leri, P. Blier, R. Uher, F. Farzan, R. Lam, G. Turecki, J. Foster, S. Rotzinger, S. Kennedy, Daniel J. Müller   +20 more
semanticscholar   +1 more source

CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel

Bagcilar Medical Bulletin, 2021
Objective:The CYP2C19*1 has an entirely normal activity allele whose clopidogrel metabolism is normal. CYP2C19*2 called as non-functional alleles. In this study, we aimed to establish the CYP2C19*1 and CYP2C19*2 genotype frequencies both in Turkish ...
Ramazan Sabırlı, Aylin Köseler, Atakan Yılmaz, İsmail Doğu Kılıç   +3 more
doaj   +1 more source

The role of CYP2C19 genotyping to guide antiplatelet therapy following ischemic stroke or transient ischemic attack

Expert Review of Clinical Pharmacology, 2022
Introduction Clopidogrel is an antiplatelet agent recommended for secondary prevention of ischemic stroke (IS) and transient ischemic attack (TIA). Conversion of clopidogrel to its active metabolite by hepatic cytochrome P450-2C19 (CYP2C19) is essential ...
J. McDermott, M. Leach, Dwaipayan Sen, Craig J. Smith, W. G. Newman, P. Bath   +5 more
semanticscholar   +1 more source